Cargando…

miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway

Chemotherapeutic resistance remains a critical clinical issue is responsible for treatment failure in patients with ovarian cancer. Evidence of the involvement of miRNAs in chemoresistance in ovarian cancer has been recently emerging. However, the underlying molecular links between chemoresistance a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Manman, Xiao, Juan, Chen, Ming, Yuan, Linjing, Li, Jundong, Shen, Hongwei, Yao, Shuzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807033/
https://www.ncbi.nlm.nih.gov/pubmed/29393390
http://dx.doi.org/10.3892/ijo.2018.4252
_version_ 1783299218876661760
author Xu, Manman
Xiao, Juan
Chen, Ming
Yuan, Linjing
Li, Jundong
Shen, Hongwei
Yao, Shuzhong
author_facet Xu, Manman
Xiao, Juan
Chen, Ming
Yuan, Linjing
Li, Jundong
Shen, Hongwei
Yao, Shuzhong
author_sort Xu, Manman
collection PubMed
description Chemotherapeutic resistance remains a critical clinical issue is responsible for treatment failure in patients with ovarian cancer. Evidence of the involvement of miRNAs in chemoresistance in ovarian cancer has been recently emerging. However, the underlying molecular links between chemoresistance and miRNAs remain largely unknown. In this study, we report that miR-149-5p expression is markedly elevated in chemoresistant ovarian cancer tissues compared with the chemosensitive ovarian cancer tissues. Furthermore, the silencing of miR-149-5p enhanced the chemosensitivity of ovarian cancer cells to cisplatin in vitro and in vivo. Conversely, the upregulation of miR-149-5p aggravated chemoresistance in ovarian cancer cells. Our results further revealed that miR-149-5p directly targeted the core kinase components of the Hippo signaling pathway, STE20-like kinase (MST)1 and protein salvador homolog 1 (SAV1), resulting in the inactivation of TEA domain (TEAD) transcription. On the whole, our findings reveal a novel mechanism of of action miR-149-5p in inducing chemotherapeutic resistance in ovarian cancer, indicating that miR-149-5p may serve as a chemotherapeutic response indicator and a potential therapeutic target in ovarian cancer.
format Online
Article
Text
id pubmed-5807033
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-58070332018-02-27 miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway Xu, Manman Xiao, Juan Chen, Ming Yuan, Linjing Li, Jundong Shen, Hongwei Yao, Shuzhong Int J Oncol Articles Chemotherapeutic resistance remains a critical clinical issue is responsible for treatment failure in patients with ovarian cancer. Evidence of the involvement of miRNAs in chemoresistance in ovarian cancer has been recently emerging. However, the underlying molecular links between chemoresistance and miRNAs remain largely unknown. In this study, we report that miR-149-5p expression is markedly elevated in chemoresistant ovarian cancer tissues compared with the chemosensitive ovarian cancer tissues. Furthermore, the silencing of miR-149-5p enhanced the chemosensitivity of ovarian cancer cells to cisplatin in vitro and in vivo. Conversely, the upregulation of miR-149-5p aggravated chemoresistance in ovarian cancer cells. Our results further revealed that miR-149-5p directly targeted the core kinase components of the Hippo signaling pathway, STE20-like kinase (MST)1 and protein salvador homolog 1 (SAV1), resulting in the inactivation of TEA domain (TEAD) transcription. On the whole, our findings reveal a novel mechanism of of action miR-149-5p in inducing chemotherapeutic resistance in ovarian cancer, indicating that miR-149-5p may serve as a chemotherapeutic response indicator and a potential therapeutic target in ovarian cancer. D.A. Spandidos 2018-01-24 /pmc/articles/PMC5807033/ /pubmed/29393390 http://dx.doi.org/10.3892/ijo.2018.4252 Text en Copyright: © Xu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Xu, Manman
Xiao, Juan
Chen, Ming
Yuan, Linjing
Li, Jundong
Shen, Hongwei
Yao, Shuzhong
miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
title miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
title_full miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
title_fullStr miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
title_full_unstemmed miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
title_short miR-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway
title_sort mir-149-5p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the hippo signaling pathway
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807033/
https://www.ncbi.nlm.nih.gov/pubmed/29393390
http://dx.doi.org/10.3892/ijo.2018.4252
work_keys_str_mv AT xumanman mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway
AT xiaojuan mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway
AT chenming mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway
AT yuanlinjing mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway
AT lijundong mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway
AT shenhongwei mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway
AT yaoshuzhong mir1495ppromoteschemotherapeuticresistanceinovariancancerviatheinactivationofthehipposignalingpathway